MGMT and glioblastoma: This finding is consistent with previous studies that suggest the prognostic value of MGMT promoter methylation dependents on the chemotherapeutic substances used.6 By conducting univariate and multivariate analysis, we confirmed that LGALS3 expression was an independent prognostic indicator of shorter OS in the proneural subtype of GBM (HR: 1.487, 95% CI: 1.229‐1.798, P < 0.001), after the adjustment of age, gender, IDH1 mutations, temozolomide chemotherapy, radiotherapy and LGALS3BP expression.